Autolus Therapeutics to Report Second Quarter 2026 Financial Results and Host Conference Call on August 11, 2026

Autolus Therapeutics (Nasdaq: AUTL) will release its second quarter 2026 financial results and operational highlights before U.S. market open on Tuesday, August 11, 2026.

Rhea-AI Summary

Autolus Therapeutics (Nasdaq: AUTL) will release its second quarter 2026 financial results and operational highlights before U.S. market open on Tuesday, August 11, 2026. Management will host a conference call and webcast at 8:30am EDT / 1:30pm BST, with pre-registration required for dial-in details, and a live webcast plus replay available in the events section of the company’s website.

Argus Aug 4 session 72 alerts

+7.14% close to close 10.5x rel. volume Open Argus

Details

News Market Reaction – AUTL

+34.2% Peak in 3 hr 42 min

$568.44M Market Cap

In the Aug 4 session, AUTL gained 7.14%, reflecting a notable positive market reaction. Argus tracked a peak move of +34.2% during that session. Our momentum scanner triggered 72 alerts that day, indicating high trading interest and price volatility. Trading volume was exceptionally heavy at 10.5x the daily average, suggesting very strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +7.1% in the session following this news. 4.46% was the strongest 24-hour reaction t...

Analysis

The stock moved +7.1% in the session following this news. 4.46% was the strongest 24-hour reaction to a prior same-tag announcement. The active S-3 shelf permits up to $150,000,000 of securities, creating a sourced financing consideration alongside the scheduled update.

Key Figures

Reporting period: Q2 2026 Results release date: August 11, 2026 Conference call time: 8:30am EDT / 1:30pm BST

Reporting period

Q2 2026

Financial results and operational highlights

Results release date

August 11, 2026

Before open of U.S. markets

Conference call time

8:30am EDT / 1:30pm BST

Management discussion of financial results and business update

Previous Conferences,earnings date Reports

2 past events · Latest: May 05

Same Type 2 events

1. May 05

   earnings date

   24h Move

   +4.5%

   First-quarter 2026 results date and conference call announcement

2. Mar 16

   earnings date

   24h Move

   +0.0%

   Fourth-quarter and full-year 2025 results date announcement

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LONDON and GAITHERSBURG, Md., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that the Company will release its second quarter 2026 financial results and operational highlights before open of U.S. markets on Tuesday, August 11, 2026.

Management will host a conference call and webcast at 8:30am EDT / 1:30pm BST to discuss the Company’s financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call.

A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website.

About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL^®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.

Contact:  

Amanda Cray 
+1 617-967-0207 
a.cray@autolus.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Autolus Therapeutics (AUTL) report its Q2 2026 financial results?

Autolus Therapeutics will report its Q2 2026 financial results on Tuesday, August 11, 2026, before the U.S. market opens. According to Autolus, the release will include financial results and operational highlights for the quarter.

What time is Autolus Therapeutics (AUTL) Q2 2026 earnings conference call on August 11, 2026?

The Autolus Therapeutics Q2 2026 conference call is scheduled for 8:30am EDT / 1:30pm BST on August 11, 2026. According to Autolus, management will discuss financial results and provide a general business update.

How can investors access the Autolus Therapeutics (AUTL) Q2 2026 earnings conference call?

Investors can access the call by pre-registering via the provided link to receive dial-in numbers and a personal PIN. According to Autolus, this PIN and dial-in information are required to join the conference call.

Will there be a webcast and replay of the Autolus Therapeutics (AUTL) Q2 2026 earnings call?

Yes, Autolus will offer a simultaneous audio webcast and replay of the Q2 2026 call. According to Autolus, both the live webcast and replay will be available in the events section of the company’s website.

What type of company is Autolus Therapeutics (AUTL) hosting the Q2 2026 call?

Autolus Therapeutics is a commercial stage biopharmaceutical company focused on next-generation programmed T cell therapies. According to Autolus, it develops, manufactures, and delivers these T cell therapies and will discuss its business during the Q2 2026 call.